ENTBF
Entheon Biomedical Corp.
OTC Markets OTCIDUSDEQUITY
DELAYED
Last price
0.00
■ 0.00 (0.00%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.00
Prev close
0.00
Day high
0.00
Day low
0.00
Volume
16
Market cap
—
P/E (TTM)
—
52W range
0.00 – 0.10
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
0.00%
+1.4%
1M
0.00%
-3.7%
3M
-94.94%
-98.0%
6M
-94.94%
-106.0%
YTD
-94.94%
-107.2%
1Y
-95.00%
-115.0%
3Y
-97.78%
-171.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $250.32K | $189.68K | — | — |
| Operating revenue | $0 | $0 | $250.32K | $189.68K | — | — |
| Cost of revenue | — | — | — | — | $12.54K | — |
| Gross profit | $0 | $0 | $250.32K | — | $9.13K | — |
| Research & development | — | — | $0 | $1.20M | $1.21M | — |
| Selling, general & admin | $334.22K | $332.66K | $563.13K | $2.59M | — | +0.5% |
| Total operating expense | $334.22K | $332.66K | $563.13K | $3.79M | — | +0.5% |
| Operating income | -$334.22K | -$332.66K | -$312.81K | -$3.60M | — | -0.5% |
| Net interest income | $10.27K | $15.11K | $7.32K | $756 | — | -32.0% |
| Pre-tax income | -$324.01K | -$317.92K | -$300.00K | -$2.06M | — | -1.9% |
| Net income | -$324.01K | -$317.92K | -$300.00K | -$8.52M | — | -1.9% |
| Net income to common | -$324.01K | -$317.92K | -$300.00K | -$8.52M | — | -1.9% |
| Basic EPS | -0.02 | -0.04 | -0.05 | -1.44 | — | +50.0% |
| Diluted EPS | -0.02 | -0.04 | -0.05 | -1.44 | — | +50.0% |
| EBIT | -$334.22K | -$332.66K | -$312.81K | -$3.60M | — | -0.5% |
| EBITDA | -$334.22K | -$332.66K | -$312.81K | -$3.60M | — | -0.5% |
| Basic shares | 13.41M | 7.74M | 5.91M | 5.91M | — | +73.2% |
| Diluted shares | 13.41M | 7.74M | 5.91M | 5.91M | — | +73.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $321.83K | $136.49K | $344.63K | $680.17K | — | +135.8% |
| Cash & short-term investments | $321.83K | $136.49K | $344.63K | $680.17K | — | +135.8% |
| Inventory | — | — | — | $0 | $26.19K | — |
| Total current assets | $348.78K | $180.14K | $396.08K | $744.22K | — | +93.6% |
| Property, plant & equipment | — | — | — | $0 | $164.13K | — |
| Goodwill & intangibles | — | — | — | $0 | $5.90M | — |
| Total assets | $353.78K | $185.14K | $401.08K | $769.22K | — | +91.1% |
| Total current liabilities | $29.75K | $39.81K | $85.33K | $154.65K | — | -25.3% |
| Total liabilities | $29.75K | $39.81K | $85.33K | $154.65K | — | -25.3% |
| Retained earnings | -$20.88M | -$20.92M | -$21.31M | -$21.61M | — | +0.2% |
| Shareholder equity | $324.03K | $145.33K | $315.75K | $614.57K | — | +123.0% |
| Working capital | $319.03K | $140.33K | $310.75K | $589.57K | — | +127.3% |
| Net tangible assets | $324.03K | $145.33K | $315.75K | $614.57K | — | +123.0% |
| Shares issued | 13.86M | 8.86M | 5.91M | 5.91M | — | +56.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$324.01K | -$317.92K | -$300.00K | -$2.06M | — | -1.9% |
| Depreciation & amortisation | — | — | $0 | $2.10K | $3.84K | — |
| Stock-based compensation | $2.71K | $0 | $1.18K | $85.31K | — | — |
| Change in working capital | $6.64K | -$37.72K | -$56.71K | $436.86K | — | +117.6% |
| Operating cash flow | -$314.66K | -$355.64K | -$359.93K | -$1.95M | — | +11.5% |
| Capital expenditure | — | — | — | — | -$97.97K | — |
| Investing cash flow | — | $0 | $24.40K | $585.64K | -$98.87K | — |
| Financing cash flow | $500.00K | $147.50K | $0 | $0 | — | +239.0% |
| Free cash flow | -$314.66K | -$355.64K | -$359.93K | -$1.95M | — | +11.5% |
| End cash position | $321.83K | $136.49K | $344.63K | $680.17K | — | +135.8% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-05-31 | 2025-02-28 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Selling, general & admin | $101.02K | $101.02K | $66.50K | $68.80K | $149.20K | 0.0% |
| Total operating expense | $101.02K | $101.02K | $66.50K | $68.80K | $149.20K | 0.0% |
| Operating income | -$101.02K | -$101.02K | -$66.50K | -$68.80K | -$149.20K | 0.0% |
| Net interest income | $1.29K | $1.29K | — | $2.31K | $3.59K | 0.0% |
| Pre-tax income | $250.28K | -$99.72K | -$65.01K | -$66.50K | -$145.61K | +351.0% |
| Net income | $255.20K | -$99.72K | -$65.01K | -$66.50K | -$145.61K | +355.9% |
| Net income to common | $255.20K | -$99.72K | -$65.01K | -$66.50K | -$145.61K | +355.9% |
| Basic EPS | 0.02 | 0.00 | — | 0.00 | -0.01 | — |
| Diluted EPS | 0.02 | 0.00 | — | 0.00 | -0.01 | — |
| EBIT | -$101.02K | -$101.02K | -$66.50K | -$68.80K | -$149.20K | 0.0% |
| EBITDA | -$101.02K | -$101.02K | -$66.50K | -$68.80K | -$149.20K | 0.0% |
| Basic shares | 13.86M | 20.61M | — | 13.86M | 12.03M | -32.8% |
| Diluted shares | 13.86M | 20.61M | — | 13.86M | 12.03M | -32.8% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-05-31 | 2025-02-28 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $324.31K | $267.60K | $321.83K | $409.38K | $525.16K | +21.2% |
| Cash & short-term investments | $324.31K | $267.60K | $321.83K | $409.38K | $525.16K | +21.2% |
| Total current assets | $517.01K | $279.13K | $348.78K | $447.26K | $558.17K | +85.2% |
| Total assets | $522.01K | $284.13K | $353.78K | $452.26K | $563.17K | +83.7% |
| Total current liabilities | $42.50K | $59.82K | $29.75K | $16.12K | $63.45K | -29.0% |
| Total liabilities | $42.50K | $59.82K | $29.75K | $16.12K | $63.45K | -29.0% |
| Retained earnings | -$20.15M | -$20.41M | -$20.88M | -$20.90M | -$21.07M | +1.3% |
| Shareholder equity | $479.51K | $224.31K | $324.03K | $436.14K | $499.72K | +113.8% |
| Working capital | $474.51K | $219.31K | $319.03K | $431.14K | $494.72K | +116.4% |
| Net tangible assets | $479.51K | $224.31K | $324.03K | $436.14K | $499.72K | +113.8% |
| Shares issued | 13.86M | 13.86M | 13.86M | 13.86M | 13.86M | -0.0% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-05-31 | 2025-02-28 | 2024-11-30 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $255.20K | -$99.72K | -$65.01K | -$66.29K | -$145.61K | — | +355.9% |
| Stock-based compensation | — | — | $0 | — | — | $0 | — |
| Change in working capital | -$198.49K | $45.49K | $4.63K | -$52.20K | $34.28K | — | -536.4% |
| Operating cash flow | $56.71K | -$54.24K | -$60.38K | -$115.78K | -$111.33K | — | +204.6% |
| Investing cash flow | — | — | — | — | — | $0 | — |
| Financing cash flow | $0 | $0 | $0 | $0 | $500.00K | — | — |
| Free cash flow | $56.71K | -$54.24K | -$60.38K | -$115.78K | -$111.33K | — | +204.6% |
| End cash position | $324.31K | $267.60K | $321.83K | $409.38K | $525.16K | — | +21.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.00
-0.00% from price
SMA 20
0.00
0.00% from price
SMA 50
0.01
-55.36% from price
SMA 100
0.04
-89.87% from price
SMA 200
0.06
-93.01% from price
EMA 12
0.00
-8.20% from price
EMA 26
0.01
-43.57% from price
EMA 50
0.02
-73.49% from price
RSI (14)
30.8
Neutral
MACD (12,26,9)
-0.00
Hist 0.00
ATR (14)
0.00
—
Realised vol 30D
618.1%
Annualised
Bollinger upper
0.00
20, 2σ
Bollinger lower
0.00
20, 2σ
50 / 200 cross
Death
0.01 vs 0.06
Trend bias
Below 200
-93.01%
Risk profile
Beta vs SPY
-1.34
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
618.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-96.2%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.00
Average true range
Beta (reported)
—
5Y monthly, from filing
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.